SkylineDx Announces Data from Largest Prospective Multi-Center Melanoma Gene Expression Profiling Trial at 21st International Congress of the Society for Melanoma Research
Source: PR News Wire, October 2024
The Merlin test (CP-GEP) stratifies melanoma patients based on risk for sentinel lymph node (SLN) metastasis, offering a powerful tool for risk-based decision-making.
ROTTERDAM, Netherlands and SAN DIEGO, Oct. 13, 2024 /PRNewswire/ — SkylineDx, an innovative diagnostics company specializing in the research and development of molecular diagnostics for oncology, inflammatory, and infectious diseases, announced today new data from the MERLIN_001 prospective US multi-center trial, the largest trial ever conducted to assess the performance of a melanoma genomic assay. The first results from this landmark study were presented in a plenary session for late-breaking abstracts at the Society for Melanoma Research (SMR) Annual Meeting in New Orleans .
The trial, conducted at nine academic sites in the United States has been successfully led by three principal investigators Dr. V. Sondak M.D., Chair of the Department of Cutaneous Oncology at Moffitt Cancer Center, Dr. T. Hieken, M.D., Surgical Oncologist and Professor of Surgery, Mayo Clinic, and Dr. M. Egger M.D., M.P.H., Associate Professor, Surgical Oncologist UofL Health Brown Cancer Center Louisville. The trial validated the predictive power of the CP-GEP (Clinical-Pathologic and Gene Expression Profile) Merlin test in identifying sentinel lymph node biopsy (SLNB) status in high risk cutaneous melanoma patients.